Navigation Links
Lexicon to Report First Quarter Financial Results on May 10, 2013
Date:5/3/2013

results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Lexicon to Provide Second Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014 Paragon 28, ... commercial launch of its foot plating system that supplants ... The GORILLA TM R3CON PLATING SYSTEM greatly enhances ... TM & Mini-Monster TM Screw Systems and ... of 10 interchangeable subsystems, the GORILLA TM R3CON ...
(Date:9/22/2014)... 2014 Research and Markets  has announced ... 2014-2018" report to their offering. ... comprehensive and up-to-date publication available covering the neurotechnology industry. ... markets, competitors, and growth rates in four key segments ... 2018. It forecasts the number of systems to be ...
(Date:9/22/2014)... , Sept. 22, 2014  Elusys Therapeutics, Inc. ... treat infectious disease, today announced it has completed ... of obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin in ... data from these studies support the safety and ... at the intended therapeutic dose. The conclusion of ...
Breaking Medicine Technology:Paragon 28, Inc. Launches the GORILLA(TM) R3CON PLATING SYSTEM 2The Market for Neurotechnology: 2014-2018 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6
... 20 Muscadine grape skin powder, from ... /), provided significant protection against radiation damage in an ... reported in April of 2009 at the 100th Annual ... Denver, Colorado.(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/CL01715 )The ...
... prototype 3D display exceeds performance expectations.LIVONIA, Mich., April 20 ... Heritage Hospital surgeons and their medical support team assembled to ... test the new LifeVision(TM) family of 3D technologies developed by ... event marks the first time in history that ...
Cached Medicine Technology:Muscadine Grape Skin Dietary Supplement Protects against Cancer Therapy Radiation Side Effects 2Oakwood Surgeons Perform World's First 3D Surgery Without Special Glasses 2Oakwood Surgeons Perform World's First 3D Surgery Without Special Glasses 3Oakwood Surgeons Perform World's First 3D Surgery Without Special Glasses 4
(Date:9/23/2014)... 23, 2014 Visiting Nurse Association (VNA) ... health care, hospice and palliative care, and community-based care ... Opening Bell last week at the New York Stock ... philanthropist and social entrepreneur to care for immigrant families ... has always worked to meet the urgent healthcare needs ...
(Date:9/23/2014)... 2014 Given the nondiscretionary nature ... Fruit and Vegetable Markets industry is generally ... benefited operators over the five years to 2014. ... and demographic trends, including a focus on healthy ... capita fruit and vegetable consumption declined at an ...
(Date:9/23/2014)... 23, 2014 Antibiotics revolutionized health care in ... once killed thousands of people. But bacteria are ... antibiotic-resistant bacteria are popping up more frequently. This ... shortage of new antibiotics and discusses the prospects ... question: Why should you finish your pills if ...
(Date:9/23/2014)... The Westlake Village sedation dentist ... sedation with treatment for new patients. Studies have shown ... anxiety or dental phobia. These common conditions are more ... patients from seeking desperately needed dental care. , Patients ... surrounding areas now have an opportunity to manage their ...
(Date:9/23/2014)... The University of Maryland Medical System was ... to pay $3 million for negligence during the delivery of ... arm [shoulder dystocia occurs after the delivery of the baby’s ... pelvic bone]. , On September 5, 2014, ... Evans, et. al. v. University of Maryland Medical Systems Corporation ...
Breaking Medicine News(10 mins):Health News:NJ's Largest Nonprofit Home Health Care Agency Joins Deutsche Bank to Ring New York Stock Exchange Opening Bell 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:The Sedation Dental Office is Now Offering Complimentary Oral Sedation with Treatment for New Patients 2Health News:The Sedation Dental Office is Now Offering Complimentary Oral Sedation with Treatment for New Patients 3Health News:Toddler Awarded $3 Million in a Shoulder Dystocia Case Against University of Maryland Medical System with Help from Attorneys at Gilman & Bedigian LLC 2Health News:Toddler Awarded $3 Million in a Shoulder Dystocia Case Against University of Maryland Medical System with Help from Attorneys at Gilman & Bedigian LLC 3
... military recreation managers to assist service ... members returning to active duty, ... military,personnel have been wounded by hostile and nonhostile acts in ... care, recreation,programming is playing an important role in reintegrating these ...
... history, study finds , , WEDNESDAY, Nov. 5 (HealthDay News) -- ... concern among parents when it comes to assessing their children,s ... by researchers at the University of Michigan C.S. Mott Children,s ... too much clout to a genetic test result. , "We ...
... team up to talk sex secrets, one night stands and ... Staying Alive,Foundation and SpinVox have teamed up with Lapeno, Mervin ... promote sexual health amongst,young people., The Telling It Like ... to speak openly about sex, sexual health and,HIV/AIDS. Young people ...
... Institute touts Grekos, breakthrough in Biomedical,Technology, WASHINGTON, ... http://www.RepairStemCells.org ) today announced that its Science ... present Emerging Frontiers in,Regenerative Stem Cell Therapy: Current ... Treatment of Various End Stage Diseases, at the,2008 ...
... Dynamics Research,Corporation (Nasdaq: DRCO ), ... technology and information technology services and,solutions to ... it,received an $11.4 million task order under ... indefinite delivery and indefinite,quantity (ID/IQ) contract, to ...
... Ingenious Med (IM), the leader in,inpatient practice ... groups and meet the increasing demand for a ... wide. Specialists are,quickly becoming an ever-growing segment of ... that Arizona based Cardiovascular Associates of Mesa,(CAM) joins ...
Cached Medicine News:Health News:Penn State Program To Help Wounded Warriors 2Health News:Most Parents Don't Overreact to Child Gene Tests 2Health News:Stars to 'Tell It Like It Is' at MTV's European Music Awards 2Health News:Stars to 'Tell It Like It Is' at MTV's European Music Awards 3Health News:Zannos Grekos, MD to Present Clinical Results of Regenerative Stem Cell Treatments to the Dubai Congress on Anti-Aging and Aesthetic Medicine 2Health News:Zannos Grekos, MD to Present Clinical Results of Regenerative Stem Cell Treatments to the Dubai Congress on Anti-Aging and Aesthetic Medicine 3Health News:Dynamics Research Corporation Awarded $11.4 Million Medical Healthcare Program Management Contract 2Health News:Dynamics Research Corporation Awarded $11.4 Million Medical Healthcare Program Management Contract 3Health News:Ingenious Med Adds Specialists to Clientele, Cardiovascular Group 2
Ribbon malleable, general purpose retractor....
The Wire Cutters are designed to cut Kirschner wires up to 2.5 mm diameter easily and smoothly. They are particularly useful for external fixation applications. The Wire Cutters shear fixation wires ...
The osteotome shafts are manufactured with stainless steel and are available both straight and curved in 1/4" and 1/2" sizes....
... Pulse CDC Compact Cardiac Digital Camera is a ... open, patient-friendly gantry, and provides full sized fields ... into your clinic you need a flexible system ... Find out how the Pulse reduces the ...
Medicine Products: